Clinical Trial

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Study acronym: BRAMLIE
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.
Trial Details
NCT Number NCT07723703
Lead Sponsor Amphista Therapeutics Ltd
Conditions Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Enrollment 54 participants
Start Date 2026-09-01
Primary Completion 2028-12-04 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23